June 8, 2022 — Take this, Omicron. Results of a COVID-19 suit trial vaccine booster reveals a “robust antibody response” against the Omicron variant, vaccine the manufacturer Moderna announced on Wednesday.
The neutralizing antibody response was eight times greater at 1 month after a 50 mcg dose with the booster containing both the original mRNA-1273 vaccine and a new vaccine in development that specifically targets the Omicron variant.
The bivalent vaccine, mRNA-1273.214, was compared to a 50 mcg dose of the original vaccine alone in 473 HIV-negative participants in the phase 2/3 trial.
These results offer the promise of greater protection against Omicron following earlier reports that showed existing COVID-19 vaccines were not as effective against the Omicron variant.
The safety and tolerability of the new vaccine were consistent with an earlier booster dose of the original vaccine, the company reported.
Moderna also has a bivalent vaccine booster in development that includes the original vaccine and a vaccine specific to the beta variant of SARS-CoV-2, the virus that causes COVID-19.
Moderna plans to file this new data with the FDA as part of its clearance application.
“We anticipate longer-lasting protection against the mRNA-1273.214 variants of concern, making it our lead candidate for recall in fall 2022,” Moderna CEO Stephane Bancel said in a statement. Press release. “We are submitting our preliminary data and analyzes to regulators in the expectation that the bivalent booster containing Omicron will be available in late summer.”